FindTrial
Sign In

A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

A Phase 2, Multicenter, Randomized, Double-Blind, Dose-Ranging Study to Evaluate IDP-107 Versus Placebo in the Treatment of Severe Acne Vulgaris With Nodules

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00666900
Enrollment
366
Registered
2008-04-25
Start date
2008-01-31
Completion date
2009-09-30
Last updated
2012-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Vulgaris

Brief summary

The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.

Interventions

DRUGLow Strength IDP-107

Once a day for 12 weeks

DRUGHigh Strength IDP-107

Once a day for 12 weeks

DRUGPlacebo Comparator

Once a day for 12 weeks

Sponsors

Dow Pharmaceutical Sciences
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Presence of inflammatory and non-inflammatory lesions

Exclusion criteria

* Dermatological conditions of the face that could interfere with clinical evaluations * Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study

Design outcomes

Primary

MeasureTime frame
Change from baseline in the number of inflammatory lesions12 weeks
Improvement from baseline in global severity12 weeks

Secondary

MeasureTime frame
Change from baseline in the number of non-inflammatory lesions12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026